Afatinib, a second-generation (2G) irreversible EGFR-TKI, also exhibits a marked efficacy against NSCLC carrying EGFR mutations, similar to the effects of gefitinib and erlotinib [19, 22]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.